Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 7Phase 1/2 2Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 3Recurrence 1Pancreatic Neoplasms 1Oligometastatic Lung Adenocarcinoma 1Neoplasm Metastasis 1NSCLC 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Neoplasms 1EGFR Mutation Positive Non-small Cell Lung Cancer 1Carcinoma 1Breast Neoplasms 1

Interventions

Exercise 112Surveys and Questionnaires 55Early Intervention, Educational 49Standard of Care 46Methods 46Magnetic Resonance Spectroscopy 45Blood Specimen Collection 44Acupuncture Therapy 44Educational Status 43Radiotherapy 36Mammography 36Control Groups 31Therapeutics 29Counseling 29Psychiatric Rehabilitation 27Cyclophosphamide 27Sentinel Lymph Node Biopsy 25Biopsy 24Yoga 20Mastectomy, Segmental 20Resistance Training 19Palliative Care 18Neoadjuvant Therapy 18High-Energy Shock Waves 18Doxorubicin 18Cognitive Behavioral Therapy 18Magnetic Resonance Imaging 17Practice Guidelines as Topic 16Paclitaxel 16Trastuzumab 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Breast Neoplasms × Erlotinib Hydrochloride × Clear all
NCT00503841 2019-04-30

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Barbara Ann Karmanos Cancer Institute

Phase NA Terminated
44 enrolled 3 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡